Proteome Sciences plc
In-vivo study shows CK1D inhibitors improve cognition in Alzheimer's model
31st December, 2012 Proteome Sciences is pleased to announce that the in-vivo study of its proprietary CK1D inhibitor programme in Alzheimer's disease was completed as anticipated in December 2012.
Having already confirmed earlier in the year that CK1D inhibitors block tau phosphorylation in cell lines in an in-vitro study, Proteome Sciences is delighted to announce that both of its lead compounds for CK1D have demonstrated improved cognitive function in the current study. These results provide important in-vivo proof of principle and demonstrate the efficacy of our compounds. The next phase will start immediately in January to undertake and complete a comprehensive assessment of biological indicators and drug levels in various tissues.
Dr. Ian Pike, Chief Operating Officer commented :-
"These results further validate PS Biomarker Services' proteomic approach in discovery of new drug targets in challenging diseases. By diligently following the tau hypothesis of Alzheimer's disease we have been able to develop exciting new therapeutic strategies that are increasingly recognised by the scientific community as important components of the fight to halt Alzheimer's disease progression. We believe that inhibiting CK1D will be an important component in treatment of AD and we will concentrate on rapidly developing these assets."
Christopher Pearce, CEO said :-
"Our goal was to deliver in-vivo proof of principle for CK1D in Alzheimer's disease. We are delighted that this has been successfully achieved in 2012. These results are most timely as major pharmaceutical companies and academia have increasingly been switching attention to the importance of tau tangles in combination with amyloid aggregation in Alzheimer's. In light of UK Government's recent commitment to fully fund NHS access to novel treatments for AD we believe there is significant potential for CK1D inhibitors to positively affect the lives of sufferers and their carers. We will continue to push our CK1D programme forward and will actively engage with the pharmaceutical industry to bring our compounds to clinical trials as soon as possible".
For further information please contact:
Proteome Sciences plc
Christopher Pearce, Chief Executive Officer
Tel: +44 (0)1932 865065
Dr. Ian Pike, Chief Operating Officer
Stephen Keys/Camilla Hume
Tel: +44 (0)20 7397 8900
Ben Atwell / Simon Conway / Mo Noonan
Tel: +44 (0)20 7269 7116
Tel: +44 (0)1483 271291
Notes to Editors:
About Proteome Sciences
Proteome Sciences is a global leader in applied proteomics and peptidomics offering high sensitivity, proprietary technologies for protein and peptide biomarker discovery, validation and assay development.
Its PS Biomarker Services™ uses isobaric and isotopic Tandem Mass Tag® (TMT®) workflows developed on the latest Orbitrap Velos and TSQ Vantage mass spectrometers to deliver rapid, robust and reproducible biomarker assay development for customers in the pharmaceutical, diagnostic and biotechnology sectors. Services are provided from its ISO 9001: 2008 accredited facilities in Frankfurt, Germany. By combining Selected Reaction Monitoring (SRM) and TMT workflows highly multiplexed assays can be developed rapidly and are suitable for screening hundreds of candidate biomarkers in larger validation studies and can be transferred for immunoassay development. The Company's own research has discovered a large number of novel protein biomarkers in key human diseases and is focused mainly in neurological/neurodegenerative conditions and in cancer. It has discovered and patented blood biomarkers, including Alzheimer's disease, stroke, brain damage and lung cancer for diagnostic and treatment applications that are available for license or are already outlicensed. Proteome Sciences, based in Cobham, UK, with facilities in London and Frankfurt, delivers outsourced proteomics services and proprietary biomarkers/biomarker assays to pharmaceutical, biotechnology and diagnostics companies.